
May 5 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
VERTEX PHARMACEUTICALS Q1 ADJUSTED EPS $4.06 VERSUS IBES ESTIMATE $4.32
VERTEX PHARMACEUTICALS Q1 TOTAL REVENUE $2.77 BILLION VERSUS IBES ESTIMATE $2.85 BILLION
VERTEX PHARMACEUTICALS OUTLOOK 2025 TOTAL REVENUE $11.85 BILLION TO $12.0 BILLION VERSUS IBES ESTIMATE OF $11.97 BILLION
VERTEX PHARMACEUTICALS: 2025 GUIDANCE INCLUDES AN IMMATERIAL COST IMPACT FROM TARIFFS
VERTEX PHARMACEUTICALS: INTANGIBLE ASSET IMPAIRMENT CHARGE OF $379.0 MILLION ASSOCIATED WITH VX-264 IN Q1